Silence Therapeutics (SLN) Earns “Buy” Rating from Peel Hunt

Share on StockTwits

Peel Hunt restated their buy rating on shares of Silence Therapeutics (LON:SLN) in a research report sent to investors on Tuesday.

SLN opened at GBX 167 ($2.15) on Tuesday. Silence Therapeutics has a 1-year low of GBX 71.88 ($0.93) and a 1-year high of GBX 254.75 ($3.29).

Silence Therapeutics Company Profile

Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various candidates for the treatment of cancer, iron overload disorders, cardiovascular disease, alcohol use disorder, and other metabolic diseases.

Recommended Story: How Do You Calculate Return on Investment (ROI)?

Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply